Lisata Therapeutics to Present at BIO CEO & Investor Conference
Lisata Therapeutics, Inc. (LSTA) announces Dr. David J. Mazzo's presentation at the BIO CEO & Investor Conference on February 26, 2024, focusing on innovative therapies for advanced solid tumors.
02/20/2024 - 08:00 AM
BASKING RIDGE, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present at the BIO CEO & Investor Conference being held on February 26-27, 2024 at the New York Marriott Marquis in New York City.
Dr. Mazzo’s presentation is on Monday, February 26, 2024 at 11:15 a.m. Eastern time. Management will also be available for in-person one-on-one meetings with investors. For those interested in meeting with management during the conference, please request a meeting through the online conference platform or reach out to John Menditto, VP of Investor Relations and Corporate Communications, at jmenditto@lisata.com . For more information regarding the BIO CEO & Investor Conference, please visit the conference website .
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1 , is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology , Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com .
Contact:
Investors and Media:
Lisata Therapeutics, Inc.
When is Dr. David J. Mazzo's presentation scheduled at the BIO CEO & Investor Conference?
Dr. David J. Mazzo's presentation is scheduled for Monday, February 26, 2024, at 11:15 a.m. Eastern time.
Where is the BIO CEO & Investor Conference taking place?
The BIO CEO & Investor Conference is being held at the New York Marriott Marquis in New York City.
Who can investors meet with during the conference?
Investors can request in-person one-on-one meetings with Lisata's management, including Dr. David J. Mazzo, through the online conference platform or by contacting John Menditto, VP of Investor Relations and Corporate Communications, at jmenditto@lisata.com.
What is Lisata Therapeutics, Inc.'s ticker symbol?
Lisata Therapeutics, Inc.'s ticker symbol is LSTA.
LSTA Rankings
#4732 Ranked by Stock Gains
LSTA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Country
US
City
Basking Ridge
About LSTA
caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.
